# Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People

> **NCT00992784** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 370 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** GSK investigational vaccine 2186877A
- **BIOLOGICAL:** FluarixTM

## Key facts

- **NCT ID:** NCT00992784
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-15
- **Primary completion:** 2010-05-27
- **Final completion:** 2010-05-27
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00992784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00992784, "Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00992784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*